Grand Pharma (00512) announced that recently, a total of six products from the group have been successfully included in the "National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug Catalog (2026)," the "Commercial Health Insurance Innovative Drug Catalog (2026)," the "Recommended List of Drugs for Commercial Health Insurance Guarantee (First Edition)" issued by the China Insurance Industry Association, or the "Drugs Involved in the Cost Measurement of Commercial Health Insurance Guarantee" issued by the China Association of Actuaries.

The six products include: Yigantai® (Yttrium[90Y] Microsphere Injection) successfully selected for the commercial insurance innovative drug catalog and recommended list for the first time; Laiteling® (Olopatadine Mometasone Nasal Spray) included in the national medical insurance drug catalog for the first time; Enzhuorun® Bishihai Le® (Indacaterol Glycopyrronium Mometasone Inhalation Powder II), Enmingrun® Bishihai Le® (Indacaterol Mometasone Inhalation Powder II, III), and Limeitong® (Eplerenone Tablets) successfully renewed and retained in the national medical insurance drug catalog; Anweide® (Carglumic Acid Dispersible Tablets) included in the commercial insurance guarantee cost table for the first time.

The group believes that the coordinated linkage between medical insurance and commercial insurance is an important measure by the state to "ensure basic needs and promote innovation," strongly supporting the high-quality development of innovative drugs. The group's six products, through multiple access pathways, are integrated into the multi-level medical security system, which will not only help improve medication accessibility for patients in related disease areas and effectively reduce treatment burdens, but also further accelerate market penetration and coverage of the products, forming a virtuous cycle from the payment end to the clinical end, laying a solid foundation for long-term high-quality growth.